CLOV
Clover Health Investments, Corp.
CLOV's fundamentals are strong: revenue grew 54% and its operating margin went from −3.3% to 0.5%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CLOV Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Strong |
CLOV's revenue, profitability, cash flow and balance sheet are all currently healthy.
CLOV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 61x | $4.88 | — |
| Cheap | 483x | $4.83 | -1% |
| Fair | 485x | $4.85 | -0.6% |
| Expensive | 487x | $4.87 | -0.2% |
| Current | 488x | $4.88 | — |
Historical ranges are pointers, not guarantees.
CLOV's PE is 488x, but its earnings don't support one, so it isn't a reliable read right now.
CLOV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for CLOV, with profitability improving.
CLOV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | +702% |
| Q3 2026 | $0.01 | +$0.12 |
| Q2 2026 | -$0.05 | +$0.03 |
| Q1 2026 | -$0.12 | -$0.07 |
| Q4 2025 | -$0.17 | -$0.08 |
| Q3 2025 | -$0.11 | +$0.07 |
| Q2 2025 | -$0.08 | +$0.17 |
| Q1 2025 | -$0.05 | +$0.28 |
| Q4 2024 | -$0.09 | +$0.35 |
CLOV has returned to profit: it earned $0.01 per share over the past year, after losing money the year before.
CLOV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $759.3M | +53% |
| Q2 2026 | $743.2M | +56% |
| Q1 2026 | $749.2M | +62% |
| Q4 2025 | $487.7M | +45% |
| Q3 2025 | $496.7M | +50% |
| Q2 2025 | $477.6M | +34% |
| Q1 2025 | $462.3M | +33% |
| Q4 2024 | $337M | -34% |
CLOV's revenue is recovering but still below its 2022 peak: $759M last quarter, up 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.8% | +5.8 points |
| Q2 2026 | 3.8% | +6 points |
| Q1 2026 | 3.6% | +3.9 points |
| Q4 2025 | -10% | -3.7 points |
| Q3 2025 | -4.9% | -2.3 points |
| Q2 2025 | -2.2% | -4.2 points |
| Q1 2025 | -0.3% | +6.3 points |
| Q4 2024 | -6.4% | +6.5 points |
CLOV's operating margin was 0.8% last quarter, up 5.8 points from the same quarter a year ago.
CLOV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $69.5M | +509% |
| Q2 2026 | $24.5M | +406% |
| Q1 2026 | $107M | +$123.5M |
| Q4 2025 | -$68.7M | +$17.4M |
| Q3 2025 | $11.4M | -77% |
| Q2 2025 | $4.8M | -89% |
| Q1 2025 | -$16.5M | -165% |
| Q4 2024 | -$86.1M | +$142.9M |
CLOV's free cash flow has turned positive again: $132M over the past year, against −$86M the year before.
CLOV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +12M shares |
| 1 year | +8.7% | +44.7M shares |
| 3 years | +16% | +76.7M shares |
| 5 years | +34% | +143M shares |
CLOV has 557M diluted shares, up 8.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $1,000 |
| Q2 2025 | — |
| Q1 2025 | $18.3M |
| Q4 2024 | — |
CLOV hasn't bought back shares in the past year.
CLOV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -18.4x | Net Cash |
CLOV has more cash than debt.
CLOV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 56.9 | Neutral |
CLOV's weekly RSI is 60 (neutral) and its Stochastic is 57 (neutral).
CLOV PE vs Healthcare Sector
CLOV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.61 | 5.9% above |
| 20 week MA | $4.55 | 7.3% above |
| 50 week MA | $3.47 | 41% above |
| 100 week MA | $3.36 | 45% above |
| 200 week MA | $2.41 | 102% above |
CLOV is in an uptrend: it's above all five of its weekly moving averages, and 102% above its 200-week average.
CLOV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.2 | $14.9 | +46% |
| 2021 | $14.9 | $4.20 | -72% |
| 2022 | $4.20 | $0.92 | -78% |
| 2023 | $0.92 | $0.95 | +3.3% |
| 2024 | $0.95 | $3.26 | +243% |
| 2025 | $3.26 | $2.51 | -23% |
| 2026 YTD | $2.51 | $4.88 | +94% |
CLOV's yearly returns have swung widely, from +243% in 2024 to −78% in 2022. It's up 94% so far in 2026.